Introduction

Many common diseases have genetic, environmental, and lifestyle antecedents that family members share, and health care professionals in the United States have long used family history information collected from individuals as a risk assessment tool. In addition, most hereditary diseases have been elucidated through the study of families. An individual’s family history has the potential to capture information about shared factors that contribute to that individual’s risk for developing common diseases, such as diabetes, stroke, cancer, and heart disease. Family history is also used routinely in many other ways, including its well-defined use in determining who might benefit from genetic testing and its use in the interpretation of genetic test results.

The combination of these attributes makes the systematic collection of family history a potentially important step in personalizing medical care. A number of tools are in development to allow family history information to be effectively incorporated into health information technology systems, including electronic health records, personal health record systems, and family history risk assessment tools. Understanding the scientific foundation of family history is important if clinical decision aids based on the information are to be useful to clinicians and individuals in typical practice settings and in improving clinical outcomes.

Although the term “family history” is in common use, it does not have a common definition—that is, it is understood differently by various clinicians and patients. Available family history questionnaires include information regarding a wide range of genetic, social,
cultural, and environmental factors. Further, family history questions may be embedded in complex risk assessment tools that incorporate many other demographic and health factors. Moreover, the very definition of family varies when viewed from the perspectives of geneticists, generalist and specialist clinicians, family therapists, and members of some ethnic and cultural groups.

The accuracy of patient-provided information is limited by an individual’s awareness, understanding, recollection, and willingness to disclose health issues of family members. The expected use of information from family history and the expected outcomes of acting on the information also vary depending on the clinical context. There are also important questions regarding the usefulness of family history information for disease prediction and improvement of individual health outcomes. Finally, the addition of new methods for systematically collecting family histories may alter the cost of care.

Given the unprecedented proliferation of genomic information and the possibility of health care reform, it is imperative to clarify the role of the family history, its validity in the primary care setting, and its effect on individual and population health outcomes. Accordingly, the National Human Genome Research Institute and the Office of Medical Applications of Research of the National Institutes of Health convened a State-of-the-Science Conference to review the topic of family history and improving health. The Planning Committee narrowed the scope of the review to family history for common diseases as seen by clinicians in primary care, specifying a review to assess the available scientific evidence regarding six questions:

- What are the key elements of a family history in a primary care setting for the purposes of risk assessment for common diseases?
- What is the accuracy of the family history, and under what conditions does the accuracy vary?
- What is the direct evidence that getting a family history will improve health outcomes for the patient and/or family?
- What is the direct evidence that getting a family history will result in adverse outcomes for the patient and/or family?
- What are the factors that encourage or discourage obtaining and using a family history?
- What are future research directions for assessing the value of family history for common diseases in the primary care setting?

The questions above defined the scope of the review, which was further limited by the Technical Expert Panel in collaboration with the McMaster Evidence-Based Practice Center (EPC). The following inclusion criteria were applied: common diseases, primary care population, and clinical outcomes recorded for individual patients rather than a group of patients. The EPC further limited the review to include only studies published in English since 1995 and reporting quantitative data. For the questions reporting clinical outcomes, only controlled interventional
trials were included. Consequently, it is important to emphasize that the review covers only a small portion of the evidence that might generally link family history to improved health.

1. **What are the key elements of a family history in a primary care setting for the purposes of risk assessment for common diseases?**

    Critical to a consideration of the value of family history in the assessment of the risk of common diseases is clarifying the key elements to establish in a primary care setting. An important limitation of a detailed ascertainment of family history is the brief length of a typical primary care visit. The standard against which this assessment can be made is the comprehensive, three-generation pedigree used in medical genetics, counseling, and research settings.

    Key elements considered by the evidence report were: (1) the number of affected relatives, (2) their sex, (3) the degree of relationship (first- or second-degree relative), (4) their age at onset, (5) ancestry (ethnicity or region of origin), and (6) lineage (maternal versus paternal relatives). Other elements of family history are not considered in this review, such as consanguinity (blood relatives) and adoption status, as well as broader patterns of inheritance that are derived from a detailed and more time-consuming family history taken by a genetic counselor or medical geneticist. In addition, other elements not considered are the impact of environmental, social, and cultural factors that may influence the incidence and outcomes of common diseases. Also, taking family histories may be helpful in establishing trust and good communication between the individual and clinician.

**What We Know**

The evidence report focused on a number of common medical conditions—asthma and allergies (atopic disease), diabetes, major depression and mood disorders, stroke, and cardiovascular or heart disease—and five of common cancers (breast, ovarian, colorectal, prostate, and lung). It expressed its findings in terms of the sensitivity and specificity of selected family history elements for identifying individuals with these conditions. The 59 studies included in the review were either (1) longitudinal in design and focused on the development (incidence) of disease, sometimes reporting more than 20 years of follow up, or (2) cross-sectional in design and, hence, focused on the association with existing (prevalent) disease.

The term sensitivity as used in this context refers to the probability that an affected individual (someone with disease) will have a positive family history for the factor in question, while specificity refers to the probability that an unaffected individual will have a negative family history. Although we would like both sensitivity and specificity to equal one, in practice the two measures tend to move in opposite directions. Thus, an increase in sensitivity is accompanied by a decrease in specificity, and vice versa. Whether one chooses to emphasize sensitivity or specificity depends on the cost of each option.

An additional measure examined in the evidence report is the predictive value of a positive family history. We say that a particular aspect of family history (for example, having an affected first-degree relative) has high positive predictive value if individuals having such a history have a high probability of also having (or developing) disease. Predictive value varies not
only with the sensitivity and specificity of the reported family history, but also with the prevalence of a disease in the population. For a given sensitivity and specificity, positive predictive value will increase as the prevalence of disease increases. By contrast, the ability of a positive family history to predict disease can be very low, despite high sensitivity and specificity, if the disease reported occurs with very low frequency in the population.

The most common family history methods covered in the evidence report were simple assessments of either any family history of a condition or history in a first-degree relative. Other aspects of family history for which information was available include family history in more distant relatives, lineage (maternal or paternal), age of onset in affected relatives, and sex of the affected relative. The evidence report provided little support to differentiate among these various measures. For virtually all of the conditions for which data are available, sensitivities and positive predictive values were very low (typically less than 25% for sensitivity and less than 10% for predictive value). Exceptions were for atopic diseases, mood disorders, and major depression, in which sensitivities were closer to 50% or more and predictive values in the 25–50% range. Specificities, by contrast, tended to be very high (typically in the 90–98% range). Atopic conditions and mental illnesses were again exceptions, with specificities ranging from 50 to 75%. Cross-sectional data, in general, generated somewhat higher sensitivities than longitudinal data. However, as stated in the evidence report, the literature supported the conclusion that family history, as currently measured in isolation, is neither a sensitive nor a highly predictive measure of common disease in individuals. Since most of the reported evidence was for recall of disease in a first-degree relative (and rarely for second-degree relative, age of onset, and lineage), and many of the data were derived from research studies in a nonprimary care setting, there is little evidence to help differentiate the key elements of a family history in a primary care setting.

What We Need To Learn

We need evidence about where and how to collect family history systematically and how best to use this information in primary care, although tools are being developed. Furthermore, it is not clear that measures of sensitivity, specificity, and predictive values are the best or even the appropriate measures to judge the relative value of key elements. Rather, approaches using relative risk and excess attributable risk of individual key elements compared to other elements (e.g., presence of disease in a first-degree relative) and multivariable models should be explored. Beyond the key elements examined in the current evidence report, there is a need to understand the value of nongenetic elements included in a family history, such as environmental, social, and cultural aspects. These elements may vary in importance and influence in different racial, ethnic, cultural, and socioeconomic groups. Little is known about the ways in which electronic health records, modular software added to electronic health records, and other information technologies may affect the standardized collection of family history.

2. What is the accuracy of the family history, and under what conditions does the accuracy vary?

The accuracy of reported family history information can be viewed from the perspective of decision theory. We wish to know the true disease history of an individual, but what we observe is a proxy’s report of that individual’s disease history. Is this information accurate? As
with the review for question 1, the evidence report again presented data in terms of sensitivity and specificity. The only difference is that, for this question, sensitivity refers to the probability that an affected family member will be correctly identified as such, while specificity refers to the probability that an unaffected family member is correctly identified as being disease-free.

**What We Know**

Unlike the traditional decision-theory framework in which the “test criterion” is a well-defined measure with stable characteristics, the properties of reported family history are likely to vary from informant to informant and to be related to personal factors such as age, gender, cultural background, education, level of cognitive functioning, and whether the individual providing the information is adopted. Additional determinants of accuracy include the condition being reported (e.g., breast cancer versus depression) and how closely related the informant is to the individual whose information is being provided (e.g., a brother, sister, or other first-degree relative versus a third cousin). In the event that an individual is cognitively impaired, family history information may need to be provided by a spouse or other surrogate informant who may be less knowledgeable about the individual’s family history. Finally, the context in which family history is obtained may be important. For instance, parents may not wish to discuss certain issues in front of their children.

The evidence report identified 35 studies that met the eligibility criteria for the review. Of these, 16 reported on the accuracy of family history of cancer, 11 on family history of mental health conditions, and 8 on other conditions. Many important conditions were not represented. In addition, an expert speaker report included two studies on the accuracy of cardiovascular disease history that were not included in the evidence report.

For those diseases included in the evidence report, specificity was generally high (90–95%), while sensitivities were lower and generally much more variable. The evidence report shows that the sensitivities for reports of various cancers ranged from 33 to 95%, while the sensitivity of mental health conditions ranged from 6 to 82%. In other words, individuals more accurately report the absence of disease than the presence of disease in family members. Much less evidence exists for other conditions, such as autoimmune disease and substance abuse, and for relatives other than first-degree relatives.

The lower accuracy for family histories of mental health disorders may be due in part to the unique challenges and issues posed by gathering such information, as described in the evidence report. Affected individuals may be a less reliable source of information about family history, and it may be necessary to use knowledgeable informants (typically relatives) to obtain such information.

The ability to assess the accuracy of family history may be hampered by lack of access to facts on the true disease state of the relatives in question and the various methods for collecting and verifying family history. Furthermore, when a response of “I don’t know” is rendered, the accuracy of family history cannot be determined.

In terms of informant characteristics, family history reports for first-degree relatives (children, siblings, and parents) appear to be more accurate than family history reports for
second- and third-degree relatives. The other frequently studied characteristic is informant’s age. In studies of cancer family histories, results have been mixed, with no consistent trend favoring reporting by younger or older individuals. However, a meta-analysis of factors associated with family psychiatric health history suggests that older informants report family history more accurately than younger informants. No consistent differences in accuracy of reporting have been noted between males and females or between informants with different educational levels, although females and those with higher educational levels tend to supply more information. The available literature also shows no consistent pattern of differences in reporting family history between informants who have disease and those who do not.

**What We Need To Learn**

Based on the limited number of studies in the evidence report, much remains unknown about the accuracy of family history. Because differences were observed across disease types and even within disease type, our knowledge of the accuracy of reported family history for specific diseases is extremely limited. Additionally, most information on this topic comes from studies conducted on patients from specialty clinics, as opposed to primary care settings. Nonetheless, in case-control studies, the accuracy of family history provided by controls (who often are drawn from primary care settings) has generally been similar to that from cases.

Little is known about how the accuracy of family history is affected by where and how family history is taken. The mode of collection could be an important factor (e.g., a paper checklist done before a clinic visit, an interactive computer tool, or in person with a clinician).

The resources necessary to significantly improve evidence on accuracy of family history will likely be substantial, and the findings may add only marginal improvements. It may be difficult to conduct feasible and economical studies in the United States, given the lack of record linkage capacity. Consensus should be sought on the acceptable level of error when assessing family history, at least as an aid to prioritizing research. High accuracy may be especially critical when the action taken based on family history is a risky screening procedure or surgical intervention, or when the procedure has significant cost for society. In these cases, additional research may well be justified.

3. **What is the direct evidence that getting a family history will improve health outcomes for the patient and/or family?**

and

4. **What is the direct evidence that getting a family history will result in adverse outcomes for the patient and/or family?**

Because it is difficult to consider the impact of the benefits of family history in the absence of potential adverse outcomes, the panel presented its report of these two questions in a single section.

Evidence exists of clinical utility for identifying individuals with genetic syndromes such as hereditary breast and ovarian cancers. Family history is also used for the assessment of risk for some common diseases where genetics plays a smaller or less clear role, such as most
diabetes, cardiovascular disease, and mental health disorders. However, the clinical utility of the family history in the primary care setting in these cases is less clear than in cases where the genetics are known and highly influential.

The evidence report process focused exclusively on direct evidence which, for the purposes of this review, included randomized controlled trials or uncontrolled studies of behavior before and after intervention. Also in this context, the term “getting a family history” meant a systematic intervention involving a family history, interpretation, and communication. The evidence report failed to identify any studies directly assessing morbidity and mortality. Rather, the outcomes of interest in the report were indirect assessments of health outcomes, such as individual screening intention, uptake of and adherence to screening tests and procedures, and preventive health behaviors. Prophylactic preventive treatment and surgery were also potential outcomes, but no randomized studies in this category were identified.

What We Know

The evidence report identified two studies that addressed whether there are benefits of systematic family history collection through increased adherence to American Cancer Society breast cancer screening guidelines over a 6- to 8-month followup period. These studies demonstrated an increase in breast self-examination and clinical breast examination but failed to show significant improvements in mammography adherence.

An assessment of the clinical utility of any intervention must also include potential adverse outcomes. The focus of the evidence report was adverse psychological impacts, primarily anxiety, from the systematic collection and interpretation of family history. However, some degree of anxiety in this context may be considered a benefit if the anxiety is a motivating factor for individuals to productively address their health risks. Inappropriate anxiety (anxiety in the absence of increased health risk) or excessive anxiety (anxiety out of proportion to the health risk) should be considered adverse outcomes. Studies that report group means for anxiety measures may not differentiate between individuals with modest increases in anxiety that may be beneficial, and those with larger increases who may experience harm.

Three studies were identified by the evidence report that addressed adverse outcomes in relation to systematic family history assessment and interpretation. These results are consistent with the literature on the psychological impacts of genetic testing that generally shows modest short-term increases in anxiety in those found at increased risk from the test, with anxiety levels returning to baseline or below over time.

What We Need To Learn

The evidence report included no studies on the value of iterative family history taken over the lifespan and, in particular, its impact on morbidity and mortality. Additionally, little is known about other potential benefits, including the impact on other family members, patient choice and locus of control, and the benefits of the family history as an indivisible component within the context of comprehensive primary care.

Furthermore, the evidence report did not address the potential harm that could result from the misinterpretation or misapplication of information from a family history that may lead to
invasive or unnecessary tests and procedures. Alternatively, the evidence report did not examine the extent to which a clinician might inappropriately reassure and fail to foster potentially beneficial measures despite a high risk of preventable disease.

The evidence report suggests that a family history intervention can motivate healthy behaviors, but the data are not sufficiently robust to conclude that a routine family history in primary care populations will lead to improved health outcomes. On the other hand, the psychological risks of a family history intervention appear to be low or nonexistent.

A relatively unique aspect of genetics is the implications of genetic information for family members of the individual. Family becomes most relevant in the consideration of potential benefits and adverse outcomes when dealing specifically with diseases associated with single gene mutations, such as hereditary breast and ovarian cancer (due to BRCA1/2 mutations) and hereditary nonpolyposis colorectal cancer (HNPCC). A family member who tests positive is faced with complex issues associated with communicating information to other family members who may now benefit from testing and possible interventions, often resulting in a host of psychosocial and clinical consequences. The resulting benefits and potential harms to family members from a family history intervention should also be considered.

5. What are the factors that encourage or discourage obtaining and using a family history?

The evidence report yielded five studies that address individual patient or provider or organizational factors that encourage or inhibit the process of obtaining and using the family history. One study focused on factors that promote or inhibit use of family history as a tool for clinical decisionmaking. Our understanding of these factors is based on the evidence report and evidence presented by experts familiar with specific factors not represented in the comprehensive review or in the peer-reviewed literature.

What We Know

Individual, family, clinician, and organizational-level factors may encourage or discourage the collection and use of family history in primary care settings. With the exception of a single study, the extant literature examined this issue as an adjunct to a clinical research question and not as the central feature of the analysis. Studies included in the evidence report explored individual, provider, and organizational factors influencing family history reporting, and the documentation of family history by the health care provider. The studies were undertaken using designs that involved observation of patient visits, mailed surveys and questionnaires, telephone interviews, and medical record review. All studies addressed the collection and use of family history among adult patients.

Individual characteristics identified through the evidence report related to increased likelihood of family history being reported are female sex, being insured, and moderate to high socioeconomic status. Clinician characteristics identified through the evidence report were residency training and length in practice, both of which were associated with a greater likelihood of clinicians taking a family history. The time spent by clinicians and the lack of tools and technology to analyze and interpret the data obtained inhibit clinicians from routinely taking a
family history. Clinicians may not be adequately compensated for the time required to obtain and interpret family history. Despite these barriers, experts noted that almost half of clinicians report collecting and using a family history in their practice. Experts reported relevance of collection of family history data outside the primary care encounter, but this was not included as an aim in studies reviewed in the evidence report.

**What We Need To Learn**

The evidence report suggested significant gaps in the science relative to individual, family, clinical, and organizational factors which affect the collection and use of family history. The design and methods used in the studies in the evidence report limit the prospects for meaningful conclusions about these factors. Specific concerns about design and methods include the lack of a consistent and clear definition of family, the impact of response bias among individuals and clinicians, and whether studies were adequately representative of the racial, social, economic, and cultural diversity and varied religious beliefs of the United States.

None of the studies in the evidence report examined whether or how individual knowledge about their family history, other than first-degree relatives, affected their ability to report this to their health care provider. There was also no evidence regarding whether an individual’s race and ethnicity, cultural background, religious beliefs, life stage, and personal health history have an effect on his or her willingness and ability to report on family history. The panel heard discussion that the presence of certain medical conditions might affect an individual’s willingness to provide family history, but they found no evidence about how these factors influenced the collection and use of a family history.

Several factors regarding clinicians’ behavior remain unexplored in the evidence report. These factors included the effect of clinicians’ attitudes, beliefs, and training on the collection and use of family history. The manner in which clinicians are reimbursed for services also has not been addressed.

The review provided no evidence of the impact that the organization and delivery of health care services have on the collection and use of family history. Integrated health care delivery systems, particularly those with electronic health records may have greater opportunities to collect and use family history. The rapid changes in medical informatics may expand this opportunity.

6. **What are future research directions for assessing the value of family history for common diseases in the primary care setting?**

The ultimate goal of collecting a family history in primary care is improvement in individual clinical outcomes and population health. Many of the questions raised by these recommendations may be addressed simultaneously in the context of single studies, but since the topic requires the expertise of multiple disciplines, the panel did not rank these research priorities.

The present evidence report did not focus on the effectiveness of family history in primary care for the identification of individuals at risk for rare genetic causes of common disorders for which early diagnosis and treatment have proven benefits. Future systematic
reviews and research efforts should evaluate family history, alone or in combination with genetic and environmental variables, for its predictive value and potential role in improving patient outcomes.

Research recommendations for short-term and intermediate goals can be grouped into three categories: (1) structure or characteristics of a family history, (2) the process of acquiring a family history, and (3) outcomes of family history acquisition, interpretation, and application.

**Structure or Characteristics of a Family History**

1. What is a parsimonious series of questions (key elements) for use as a family history screening tool in primary care practice?

2. What are the environmental and lifestyle elements of a family history that are most useful in helping patients make positive changes in health-related behaviors?

3. What are the best methods and key elements to collect family history across multiple common disease entities (e.g., multiple diseases versus one)?

4. How do the accuracy and completeness of family history information vary according to the setting in which it is collected (e.g., specialty care, primary care, community outreach, the Internet)?

5. What is the optimal frequency for ascertaining and updating family history?

6. What are the best tools and methods for family history collection and interpretation?

7. What personnel and information technology resources and settings facilitate the collection of family histories that meet individual, community, and clinical goals?

8. What are the best statistical approaches to ascertain the benefit of one key element of family history relative to another element?

9. How does the definition of family in diverse racial, ethnic, religious, social, cultural, and economic population groups influence the collection and use of family history?

10. Do key elements of family history vary by race, ethnicity, religious belief, life stage, socioeconomic status, and culture?

11. How do family dynamics and health disorders affect an individual’s awareness and ability to report on family health history?

**Process of Acquiring a Family History**

12. Who is the best family informant to convey a family history (i.e., the “family history expert”)?

13. To what extent do demographic factors modify an informant’s ability to provide an accurate family history?
14. How might individuals, their families, and communities be best engaged in the collection of family history over time?

15. What are methods to minimize the time for collecting family history? Are there approaches to the assessment of family history across several office visits, self-administered questionnaires, ancillary personnel, or record linkage that are effective?

16. How do the clinician’s knowledge, attitudes, beliefs, training, and skills influence the ability to collect, interpret, and use family history?

17. How might family history, including environmental and behavioral risk factors, be improved by a systematic, technology-supported approach (e.g., electronic health records, record linkage, enhancing communication between family members)?

18. What are optimal ways to use family history in a primary care setting to identify individuals who can benefit from enhanced surveillance or referral to genetics services?

19. What are the key facilitators, incentives, and barriers for clinicians, individuals, families, and organizations for the collection of family history in primary care practice?

**Expected Outcomes of Family History Interpretation**

20. Besides disease risk assessment, what are the additional potential benefits to the individual, family, and clinician in taking a thorough family history; e.g., building trust and partnering through a personal interview in a primary care setting?

21. How and why does family history information change the behavior of the clinician?

22. How are family history interpretations and findings best communicated to the individual and family to change health and disease prevention and detection behaviors over time? What strategies will minimize potential harms?

23. What are the short- and long-term effects on individuals, families, and clinicians of inaccurate, misinterpreted, or unavailable family history information?

24. Can family history information be linked to genomic information or to important intermediate markers of common chronic diseases (e.g., body mass index, drug adherence, tobacco cessation) to predict change in outcome?

25. What are the short- and long-term effects on family dynamics of systematic family history taking in diverse populations and cultural settings?
Conclusions

The panel recognized that family history has an important role in the practice of medicine and may motivate positive lifestyle changes, enhance individual empowerment, and influence clinical interventions. The panel found that it is unclear how this information can be effectively gathered and used in the primary care setting for common diseases.

The emerging international paradigm on using evidence-based methods to evaluate tests and interventions works best when one can trace a linear pathway from test development through randomized controlled trials that anchor usefulness in clinical practice with quantitative evidence of benefits and harms (principles best exemplified in the field of genetics by the ACCE and Evaluation of Genomic Applications in Practice and Prevention methodologies). Family history was a core element of clinical care long before the evidence-based medicine paradigm was even proposed. Therefore, it comes as no surprise that the evidence base supporting family history for common diseases in primary care, as assessed in this state-of-the-science review, is weak in defining the key elements, assessing test performance, linking results to clinical conditions, acting on results in specific clinical scenarios, evaluating potential benefits and harms, and assessing factors encouraging and discouraging use of family history. For a systematically collected family history for common diseases to become an evidence-based tool in primary care clinical settings, substantial additional research will be needed. Challenges include the number, complexity, and cost of rigorous studies that have potential to adequately address the scientific questions outlined in this panel's research recommendations. The relative priority of specific research questions on family history in the context of other health information and genetic technologies and interventions that might address the same clinical problems in different ways requires debate in order to ensure the best outcomes for improving health.
Consensus Development Panel

Alfred O. Berg, M.D., M.P.H.
Panel and Conference Chairperson
Professor
Department of Family Medicine
University of Washington
Seattle, Washington

Macaran A. Baird, M.D., M.S.
Professor and Head
Department of Family Medicine and
Community Health
University of Minnesota
Minneapolis, Minnesota

Jeffrey R. Botkin, M.D., M.P.H.
Professor of Pediatrics
Department of Pediatrics
Adjunct Professor of Medicine
Department of Internal Medicine
Division of Medical Ethics
Associate Vice President for Research
Integrity
University of Utah School of Medicine
Salt Lake City, Utah

Deborah A. Driscoll, M.D.
Luigi Mastroianni, Jr., Professor and Chair
Department of Obstetrics and Gynecology
University of Pennsylvania Health System
Philadelphia, Pennsylvania

Paul A. Fishman, Ph.D.
Scientific Investigator/Health Economist
Group Health Research Institute
Group Health Cooperative
Seattle, Washington

Peter D. Guarino, Ph.D., M.P.H.
Cooperative Studies Program Coordinating
Center
Department of Veterans Affairs Connecticut
Healthcare Systems
West Haven, Connecticut

Robert A. Hiatt, M.D., Ph.D.
Professor and Co-Chair
Department of Epidemiology and
Biostatistics
Director, Population Sciences and
Deputy Director, Helen Diller Family
Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Gail P. Jarvik, M.D., Ph.D.
Head, Division of Medical Genetics
Arno G. Motulsky Professor of Medicine
Professor of Genome Sciences
University of Washington Medical Center
Seattle, Washington

Sandra Millon-Underwood, Ph.D., R.N.,
F.A.A.N.
Professor
College of Nursing
University of Wisconsin–Milwaukee
Milwaukee, Wisconsin

Thomas M. Morgan, M.D.
Assistant Professor of Pediatrics
Division of Genetics and Genomic Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee

John J. Mulvihill, M.D.
Professor of Pediatrics
Children’s Medical Research Institute
Kimberly V. Talley Chair in Genetics
University of Oklahoma Health Sciences
Center
Oklahoma City, Oklahoma

Toni I. Pollin, Ph.D., M.S.
Assistant Professor of Medicine
Division of Endocrinology, Diabetes, and
Nutrition
University of Maryland School of Medicine
Baltimore, Maryland
Selma R. Schimmel  
Founder and CEO  
Vital Options International  
Host, The Group Room® cancer talk radio show  
Los Angeles, California

Michael Edward Stefanek, Ph.D.  
Vice President  
Behavioral Research  
Director  
Behavioral Research Center  
American Cancer Society  
Atlanta, Georgia

Louise S. Acheson, M.D., M.S.  
Professor  
Department of Family Medicine  
Case Western Reserve University  
University Hospitals Case Medical Center  
Cleveland, Ohio

Ted D. Adams, Ph.D., M.P.H.  
Adjunct Assistant Professor  
Cardiovascular Genetics Division  
University of Utah School of Medicine  
Program Director  
Health and Fitness Institute, LDS Hospital, Intermountain Healthcare  
Salt Lake City, Utah

Liany E. Arroyo, M.P.H, C.P.H.  
Director, Institute for Hispanic Health  
National Council of La Raza  
Washington, DC

Siobhan M. Dolan, M.D., M.P.H.  
Associate Professor of Obstetrics and Gynecology and Women’s Health  
Albert Einstein College of Medicine  
Montefiore Medical Center  
Consultant to March of Dimes  
Bronx, New York

William M. Vollmer, Ph.D.  
Senior Investigator  
Center for Health Research  
Kaiser Permanente Northwest  
Portland, Oregon

Janet K. Williams, Ph.D., R.N., P.N.P., F.A.A.N.  
Kelting Professor of Nursing  
Director, Clinical Genetics Research  
Postdoctoral Fellowship  
University of Iowa  
Iowa City, Iowa

Jon Emery, M.B.B.Ch., D.Phil., M.A., FRACGP  
Head, School of Primary, Aboriginal and Rural Health Care  
Professor, Department of General Practice  
University of Western Australia  
Claremont, Western Australia  
Australia

Ridgely Fisk Green, Ph.D., M.M.Sc.  
TKC Integration Services Contractor  
National Center on Birth Defects and Developmental Disabilities  
Centers for Disease Control and Prevention  
Atlanta, Georgia

James E. Haddow, M.D.  
Co-Director  
Division of Medical Screening and Special Testing  
Womens and Infants Hospital of Rhode Island  
Professor (Research)  
Department of Pathology and Laboratory Medicine  
Warren Alpert Medical School of Brown University  
Standish, Maine
Chanita Hughes Halbert, Ph.D.
Associate Professor
Department of Psychiatry
Director
Community-Based Research and Cancer Disparities Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Kevin S. Hughes, M.D., F.A.C.S.
Surgical Director, Breast Screening
Co-Director, Avon Comprehensive Breast Evaluation Center
Massachusetts General Hospital
Associate Professor of Surgery
Harvard Medical School
Boston, Massachusetts

Muin J. Khoury, M.D., Ph.D.
Senior Consultant in Public Health Genomics
National Cancer Institute
Director, Office of Public Health Genomics
Centers for Disease Control and Prevention
Atlanta, Georgia

Colleen M. McBride, Ph.D.
Chief, Social and Behavioral Research Branch
National Human Genome Research Institute
National Institutes of Health
Bethesda, Maryland

Harvey J. Murff, M.D., M.P.H.
Assistant Professor of Medicine
Institute for Medicine and Public Health
Vanderbilt University
Nashville, Tennessee

Clinical Associate Professor in Primary Care Division of Primary Care
School of Graduate Entry Medicine and Health
University of Nottingham
Derby City General Hospital
Derby, Derbyshire
United Kingdom

Scott D. Ramsey, M.D., Ph.D.
Professor, Department of Medicine
University of Washington School of Medicine
Director, Cancer Prevention Clinic
Seattle Cancer Care Alliance
Member, Public Health Sciences
Fred Hutchinson Cancer Research Center
Seattle, Washington

Eugene C. Rich, M.D., F.A.C.P.
Professor of Medicine
Creighton University School of Medicine
Scholar in Residence
Association of American Medical Colleges
Washington, DC

Wendy S. Rubinstein, M.D., Ph.D., F.A.C.P., FACMG
Medical Director
Center for Medical Genetics
NorthShore University HealthSystem
Clinical Associate Professor of Medicine
University of Chicago
Pritzker School of Medicine
Evanston, Illinois

P. Lina Santaguida, Ph.D.
Assistant Professor
Department of Clinical Epidemiology and Biostatistics
Associate Director
McMaster University Evidence-Based Practice Centre
Hamilton, Ontario
Canada

Maren T. Scheuner, M.D., M.P.H., FACMG
Natural Scientist, RAND Corporation
Research Health Scientist
Veterans Administration Greater Los Angeles Healthcare System
Adjunct Associate Professor
Department of Health Services
University of California, Los Angeles School of Public Health
Santa Monica, California

Sharon F. Terry, M.A.
President and CEO
Genetic Alliance
Washington, DC
Planning Committee members provided their input at a meeting held March 3–5, 2008.
The information provided here was accurate at the time of that meeting.
Planning Committee members provided their input at a meeting held March 3–5, 2008. The information provided here was accurate at the time of that meeting.
Kelli K. Marciel, M.A.
Communications Director
Office of Medical Applications of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

Clement J. McDonald, M.D.
Director, Lister Hill Center
National Library of Medicine
National Institutes of Health
Bethesda, Maryland

Kathleen Ries Merikangas, Ph.D.
Senior Investigator
Section on Developmental Genetic Epidemiology
National Institute of Mental Health
National Institutes of Health
Bethesda, Maryland

Lata S. Nerurkar, Ph.D.
Senior Advisor for the Consensus Development Program
Office of Medical Applications of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

James C. O’Leary
Chief Operating Officer
Genetic Alliance, Inc.
Washington, DC

Dina N. Paltoo, Ph.D., M.P.H.
Program Director
Advanced Technologies and Surgery Branch
Division of Cardiovascular Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

Gurvaneet Randhawa, M.D., M.P.H.
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality
Rockville, Maryland

RADM Penelope Slade Royall, P.T., M.S.W.
DASH–Prevention Priority Director
Office of the Secretary
Office of Public Health and Science
U.S. Department of Health and Human Services
Rockville, Maryland

Maren T. Scheuner, M.D., M.P.H., FACMG
Natural Scientist
Research Health Scientist
Adjunct Associate Professor
RAND Corporation
Veterans Administration Greater Los Angeles Healthcare System
Department of Health Services
University of California, Los Angeles
School of Public Health
Santa Monica, California

Emmanuel A. Taylor, Dr.P.H., M.Sc.
Health Scientist Administrator
Center to Reduce Cancer Health Disparities
National Cancer Institute
National Institutes of Health
Rockville, Maryland

Louise Wideroff, Ph.D., M.S.P.H.
Risk Factor Monitoring and Methods Branch
Applied Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Marc S. Williams, M.D., F.A.A.P., FACMG
Director, Intermountain Healthcare Clinical Genetics Institute
Salt Lake City, Utah

Paula W. Yoon, Sc.D., M.P.H.
Epidemiologist
Division for Heart Disease and Stroke Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia

Planning Committee members provided their input at a meeting held March 3–5, 2008. The information provided here was accurate at the time of that meeting.
Conference Sponsors

National Human Genome Research Institute
Alan E. Guttmacher, M.D.
Acting Director

The Johns Hopkins University School of Medicine, Educational Provider
Todd Dorman, M.D., F.C.C.M.
Associate Dean and Director, CME

Office of Medical Applications of Research
Jennifer Miller Croswell, M.D.
Acting Director

Conference Cosponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development
Duane Alexander, M.D.
Director

National Institute on Alcohol Abuse and Alcoholism
Kenneth R. Warren, Ph.D.
Acting Director

National Cancer Institute
John E. Niederhuber, M.D.
Director

National Institute on Drug Abuse
Nora D. Volkow, M.D.
Director

National Heart, Lung, and Blood Institute
Elizabeth G. Nabel, M.D.
Director

National Library of Medicine
Donald Lindberg, M.D.
Director

National Institute of Mental Health
Thomas R. Insel, M.D.
Director

Office of Rare Diseases Research
Stephen C. Groft, Pharm.D.
Director

National Institute of Nursing Research
Patricia Grady, Ph.D., R.N., F.A.A.N.
Director

Office of Research on Women’s Health
Vivian W. Pinn, M.D.
Director

Conference Partners

Centers for Disease Control and Prevention
Thomas R. Frieden, M.D., M.P.H.
Director

Office of the Surgeon General
RADM Steven K. Galson, M.D., M.P.H.
Acting Surgeon General

Maternal and Child Health Bureau, Health Resources and Services Administration
Peter C. Van Dyck, M.D., M.P.H., M.S.
Associate Administrator